Clinical Assessment and Management of Comorbid Mood and Anxiety Disorders

Comorbidity between mood and anxiety disorders is highly prevalent and contributes to greater illness severity, chronicity and functional impairment than either condition alone. Clinical assessment requires a comprehensive approach that integrates categorical diagnoses with dimensional specifiers such as anxious distress or anxious depression. Standardised interviews and validated rating scales are essential for identifying overlapping symptom domains, distinguishing primary from secondary presentations, and monitoring treatment response. Management strategies combine pharmacological and psychological interventions tailored to the individual’s symptom profile and comorbid complexity. Selective serotonin reuptake inhibitors and serotonin–noradrenaline reuptake inhibitors remain first-line treatments, often supplemented by augmentation strategies and close monitoring for side effects. Cognitive behavioural therapy and transdiagnostic psychotherapies address shared cognitive and behavioural mechanisms, while collaborative care models and digital health tools enhance treatment access and patient engagement. Emerging biomarkers from neuroimaging and inflammatory studies promise to refine prognostic stratification and guide personalised interventions. Integrated care pathways that bridge primary and specialist services are critical for improving outcomes and reducing the global burden of these co-occurring disorders.

Research from Nature Portfolio

A seminal report examined the prevalence and impact of co-occurring generalised anxiety disorder in patients with major depressive disorder and found that over 70% of depressed outpatients met criteria for generalised anxiety. Comorbidity was associated with significantly lower physical and psychological quality-of-life scores, underlining the necessity of routine dual-axis screening and comprehensive treatment planning. The findings support integrated assessment frameworks that capture both mood and anxiety dimensions and suggest that coordinated care addressing both disorders yields better functional outcomes than treatments targeting a single diagnostic category.

Clinical Assessment and Management of Comorbid Mood and Anxiety Disorders publication trend

The graph below shows the total number of articles in clinical assessment and management of comorbid mood and anxiety disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Comorbidity: Co-occurrence of two or more psychiatric disorders in the same individual.

Anxious depression: A subtype of depressive disorder characterised by prominent anxiety symptoms alongside core features of depression.

Anxious distress specifier: A DSM-5 dimensional indicator denoting the presence of significant anxiety symptoms within a mood episode.

Psychophysiological interaction: An fMRI analysis technique that examines task-related changes in connectivity between brain regions.

Quality of life (QOL): A multidimensional construct assessing physical, psychological and social well-being.

References

1. Co‐morbidity between mood and anxiety disorders: A systematic review and meta‐analysis. Depression and Anxiety (2020).
2. Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder. Scientific Reports (2017).
3. Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder. NeuroImage Clinical (2023).